Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target.
Abiraterone Acetate
/ pharmacology
Aged
Aged, 80 and over
Animals
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Biomarkers, Tumor
Cell Cycle
/ drug effects
Cell Line, Tumor
Cell Survival
/ drug effects
Checkpoint Kinase 1
/ antagonists & inhibitors
Disease Models, Animal
Female
High-Throughput Nucleotide Sequencing
Humans
Immunohistochemistry
Mice
Middle Aged
Neoplasm Grading
Neoplasm Staging
Protein Kinase Inhibitors
/ pharmacology
Receptors, Androgen
/ metabolism
Triple Negative Breast Neoplasms
/ drug therapy
Xenograft Model Antitumor Assays
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 01 2019
15 01 2019
Historique:
received:
24
05
2018
revised:
28
08
2018
accepted:
18
10
2018
pubmed:
26
10
2018
medline:
28
2
2020
entrez:
25
10
2018
Statut:
ppublish
Résumé
Our aim was to identify predictive factors of abiraterone acetate efficacy and putative new druggable targets in androgen receptor (AR)-positive triple-negative breast cancer (TNBC) treated in the UCBG 2012-1 trial. Classic IHC apocrine markers including AR, FOXA1, GGT1, and GCDFP15, from patients' tumors allowed identifying abiraterone acetate-responders and nonresponders. All responders had clear apocrine features. Transcriptome analysis revealed that 31 genes were differentially expressed in the two subgroups, 9 of them being linked to proliferation and DNA damage repair. One of the most significant differences was the overexpression, in nonresponders, of This study suggests that apocrine features can be helpful in the identification of abiraterone acetate-responders. We identified Chk1 as a putative drug target in AR-positive TNBCs.
Identifiants
pubmed: 30352905
pii: 1078-0432.CCR-18-1469
doi: 10.1158/1078-0432.CCR-18-1469
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Protein Kinase Inhibitors
0
Receptors, Androgen
0
CHEK1 protein, human
EC 2.7.11.1
Checkpoint Kinase 1
EC 2.7.11.1
Abiraterone Acetate
EM5OCB9YJ6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
856-867Informations de copyright
©2018 American Association for Cancer Research.